Edition:
India

Biosig Technologies Inc (BSGM.OQ)

BSGM.OQ on NASDAQ Stock Exchange Capital Market

4.64USD
2:29am IST
Change (% chg)

$0.10 (+2.20%)
Prev Close
$4.54
Open
$4.59
Day's High
$4.75
Day's Low
$4.57
Volume
47,098
Avg. Vol
148,255
52-wk High
$12.43
52-wk Low
$2.37

Latest Key Developments (Source: Significant Developments)

Viralclear Expands Ongoing Phase 2 Trial Size For Its Oral Anti-Viral For Treatment Of Covid-19
Tuesday, 22 Sep 2020 

Sept 22 (Reuters) - Biosig Technologies Inc ::VIRALCLEAR EXPANDS ONGOING PHASE 2 TRIAL SIZE FOR ITS ORAL ANTI-VIRAL FOR THE TREATMENT OF COVID-19, EXPANDS TRIAL LOCATIONS AND APPOINTS CONTRACT MANUFACTURING ORGANIZATION TO MANUFACTURE PHASE 3 SUPPLIES OF MERIMEPODIB ORAL SOLUTION.BIOSIG TECHNOLOGIES INC - SIZE OF ONGOING PHASE 2 TRIAL OF MERIMEPODIB IN COMBINATION WITH REMDESIVIR INCREASED FROM 40 TO 80 SUBJECTS.BIOSIG TECHNOLOGIES INC - ADDED 2 NEW PRINCIPAL INVESTIGATORS FOR ONGOING PHASE 2 TRIAL EXPANDING TOTAL NUMBER OF LOCATIONS TO 10.BIOSIG TECHNOLOGIES INC - CMO APPOINTED TO MANUFACTURE PHASE 3 SUPPLIES OF MERIMEPODIB ORAL SOLUTION.BIOSIG TECHNOLOGIES INC - MERIMEPODIB MONOTHERAPY TRIAL TO BE CONDUCTED IN OUTPATIENT SETTING AFTER CURRENT COMBINATION TRIAL COMPLETES.BIOSIG TECHNOLOGIES- ONCE ADDITIONAL SUBJECTS ARE ENROLLED, FURTHER CLINICAL DATA IS GOT, TEAM TO DISCUSS WITH FDA APPROPRIATE SIZE FOR PHASE 3 TRIAL.  Full Article

Biosig Technologies Inc Announces $17.5 Million Common Stock Only Registered Direct Offering
Wednesday, 24 Jun 2020 

June 24 (Reuters) - Biosig Technologies Inc ::BIOSIG TECHNOLOGIES, INC. ANNOUNCES $17.5 MILLION COMMON STOCK ONLY REGISTERED DIRECT OFFERING.BIOSIG TECHNOLOGIES - ANNOUNCES REGISTERED DIRECT OFFERING OF 2.2 MILLION SHARES OF COMMON STOCK, AT $8.00 PER SHARE.BIOSIG TECHNOLOGIES - TO USE NET PROCEEDS FROM OFFERING TO SUPPORT COMMERCIALIZATION, AMONG OTHER THINGS.  Full Article

FDA Clears Application For Phase II Trial Of Viralclear’S Merimepodib To Treat Covid-19
Monday, 18 May 2020 

May 18 (Reuters) - Biosig Technologies Inc ::FDA CLEARS THE INVESTIGATIONAL NEW DRUG APPLICATION TO ENABLE THE PHASE II TRIAL OF VIRALCLEAR’S MERIMEPODIB, ORAL SOLUTION TO TREAT ADULT PATIENTS WITH ADVANCED COVID-19, TO PROCEED.BIOSIG TECHNOLOGIES INC - PHASE II CLINICAL TRIAL EXPECTED TO BE CONDUCTED AT MULTIPLE CENTERS IN UNITED STATES.  Full Article

Biosig Technologies Says Co's Unit Entered Into Know-How License Agreement With Mayo Foundation
Monday, 13 Apr 2020 

April 13 (Reuters) - Biosig Technologies Inc ::BIOSIG TECHNOLOGIES INC - ON APRIL 8, CO'S UNIT ENTERED INTO KNOW-HOW LICENSE AGREEMENT WITH MAYO FOUNDATION.BIOSIG - AGREEMENT GRANTS UNIT EXCLUSIVE WORLDWIDE LICENSE WITH RIGHT TO SUBLICENSE.BIOSIG - LICENSE GRANTED FOR CERTAIN PATENT RIGHTS FOR DEVELOPMENT & COMMERCIALIZATION OF PRODUCTS, METHODS, AND PROCESSES FOR PUBLIC USE AND BENEFIT.  Full Article

Positive Data Generated By Biosig Subsidiary ViralClear On COVID-19 Coronavirus Published In BioRxiv
Thursday, 9 Apr 2020 

April 9 (Reuters) - Biosig Technologies Inc ::POSITIVE DATA GENERATED BY BIOSIG SUBSIDIARY VIRALCLEAR ON COVID-19 CORONAVIRUS PUBLISHED IN BIORXIV.BIOSIG TECHNOLOGIES INC - VICROMAX SHOWN TO DECREASE VIRAL PRODUCTION OF COVID -19 CORONAVIRUS BY OVER 98%.BIOSIG TECHNOLOGIES - INTENDS TO PURSUE DEVELOPMENT OF AGENT FOR TREATMENT OF COVID-19 THROUGH FDA-APPROVED CLINICAL TRIALS IN Q2 2020.  Full Article

Biosig Subsidiary Neuroclear Acquires License For A Broad-Spectrum Anti-Viral Agent That May Treat COVID-19
Wednesday, 25 Mar 2020 

March 25 (Reuters) - Biosig Technologies Inc ::BIOSIG SUBSIDIARY NEUROCLEAR ACQUIRES LICENSE FOR A BROAD-SPECTRUM ANTI-VIRAL AGENT THAT MAY TREAT COVID-19. LABORATORY RESULTS DEMONSTRATE HIGH LEVEL OF ACTIVITY AGAINST COVID-19 IN CELL CULTURE.BIOSIG TECHNOLOGIES INC - INTENDS TO PURSUE DEVELOPMENT OF AGENT FOR TREATMENT OF COVID-19 THROUGH FDA-APPROVED CLINICAL TRIALS..BIOSIG TECHNOLOGIES INC - EXPECTS THAT VICROMAX(TM) COULD BE USED ALONE OR IN A COMBINATION WITH OTHER ANTI-VIRAL AGENTS OR IMMUNE MODULATORS.BIOSIG - ORALLY ADMINISTERED, BROAD-SPECTRUM ANTI-VIRAL AGENT VICROMAX DEMONSTRATED STRONG ACTIVITY AGAINST COVID-19 IN CELL CULTURES IN LAB TESTING.BIOSIG TECHNOLOGIES INC - APPOINTED NICK SPRING AS CEO OF VIRALCLEAR AND STEVE KING AS COO.BIOSIG TECHNOLOGIES INC - VICROMAX WAS ADDED TO A TISSUE CULTURE ASSAY FOR SARS-CO-2 CORONAVIRUS AND AN ANTI-VIRAL EFFECT WAS OBSERVED.BIOSIG TECHNOLOGIES - INTENDS TO DEVELOP VICROMAX AND TAKE IT THROUGH CLINICAL TRIALS UNDER A NEW NEUROCLEAR SUBSIDIARY, VIRALCLEAR PHARMACEUTICALS.  Full Article

Biosig Announces $10 Million Public Offering Of Common Stock
Friday, 21 Feb 2020 

Feb 21 (Reuters) - Biosig Technologies Inc ::BIOSIG ANNOUNCES $10 MILLION PUBLIC OFFERING OF COMMON STOCK.BIOSIG TECHNOLOGIES INC - AGREED TO SELL 2.5 MILLION SHARES OF ITS COMMON STOCK, $0.001 PAR VALUE PER SHARE.  Full Article

Biosig Technologies Announces Proposed Public Offering Of Common Stock
Friday, 21 Feb 2020 

Feb 20 (Reuters) - Biosig Technologies Inc ::BIOSIG ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

BioSig Technologies' Subsidiary, Neuroclear Technologies Raised $3.7 Mln In Initial Funding
Thursday, 14 Nov 2019 

Nov 14 (Reuters) - Biosig Technologies Inc ::BIOSIG TECHNOLOGIES - HAS ISSUED ITS NOVEMBER 2019 SHAREHOLDER LETTER - SEC FILING.BIOSIG TECHNOLOGIES - CO'S SUBSIDIARY, NEUROCLEAR TECHNOLOGIES, INC., RAISED $3.7 MILLION IN INITIAL FUNDING.BIOSIG TECHNOLOGIES - ENDED THIRD QUARTER WITH A CASH BALANCE OF APPROXIMATELY $12.3 MILLION.BIOSIG TECHNOLOGIES - IN 2020, EXPECT TO SEE FIRST COMMERCIAL REVENUES.  Full Article

Biosig Technologies Files For Resale Of Up To 2.16 Mln Shares Of Common Stock By Selling Stockholders
Saturday, 1 Jun 2019 

May 31 (Reuters) - Biosig Technologies Inc ::BIOSIG TECHNOLOGIES INC FILES FOR RESALE OF UP TO 2.16 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article